Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, commonly known as Vertex, is a leading biotechnology company headquartered in the United States. Founded in 1989, Vertex has established itself as a pioneer in the development of transformative therapies for serious diseases, particularly in the field of cystic fibrosis. With major operational regions across North America and Europe, the company focuses on innovative drug discovery and development. Vertex is renowned for its unique portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, and Trikafta, which have significantly improved the quality of life for patients. The company’s commitment to research and development has positioned it as a market leader, achieving notable milestones such as the first approved therapy for the underlying cause of cystic fibrosis. Vertex continues to drive advancements in biotechnology, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Vertex Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vertex Pharmaceuticals's score of 38 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Vertex Pharmaceuticals's reported carbon emissions
In 2023, Vertex Pharmaceuticals reported total carbon emissions of approximately 474,129,000 kg CO2e, with emissions distributed across various scopes: 7,670,000 kg CO2e from Scope 1, 4,888,000 kg CO2e from Scope 2, and 474,129,000 kg CO2e from Scope 3. This reflects a significant reliance on indirect emissions, particularly from supply chain activities. In previous years, Vertex's emissions have shown fluctuations, with 2022 emissions at about 249,816,000 kg CO2e, and 2021 at approximately 249,816,000 kg CO2e. The company has not publicly disclosed specific reduction targets or initiatives, indicating a potential area for improvement in their climate commitments. Overall, while Vertex Pharmaceuticals has made strides in tracking and reporting its emissions, the absence of defined reduction targets suggests that further action may be necessary to align with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vertex Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
